CHOSEN Raises $5M Series A Led by Fireside Ventures
Investors observe a scientist working in a lab focused on advanced skincare research.
Key Highlights
Skincare startup CHOSEN secures $5 million Series A funding led by Fireside Ventures and L’Oréal’s BOLD arm for R&D expansion.
CHOSEN Closes $5 Million Series A Funding Round
Bengaluru-based skincare innovator CHOSEN has announced the successful closure of its Series A funding round, securing $5 million. The investment round was co-led by prominent venture capital firm Fireside Ventures and BOLD, the strategic investment arm of global beauty giant L’Oréal. Alkemi Growth Capital also participated in the round, underscoring a strong vote of confidence in CHOSEN’s unique approach to science-led skincare.
Strategic Backing from Industry Leaders and Experts
The Series A funding round saw significant participation beyond the lead investors. Angel investor Avnish Anand contributed to the round, alongside a notable group of dermatologists. This expert backing includes contributions from Dr. Chandan Asokan, Dr. KC Nischal, Dr. Punit Saraogi, Dr. Nishita Ranka, and Dr. Mikki Singh, highlighting the clinical credibility and potential recognized by the medical community.
CHOSEN’s Science-Led Skincare Model
Founded in 2020 by cosmetic dermatologist Dr. Renita Rajan, CHOSEN has carved a niche by focusing on science-led skincare solutions specifically tailored for melanin-rich Indian skin. The company’s philosophy is deeply rooted in the concept of the exposome, acknowledging the profound impact of environmental and lifestyle factors on skin health. CHOSEN operates on a distinctive clinic-to-consumer model, integrating dermatology-led product development with direct-to-consumer distribution channels to ensure efficacy and consumer reach.
Funding to Fuel Research, Expansion, and Hiring
The newly acquired capital will be strategically deployed to enhance CHOSEN’s research and development capabilities, further expand its pipeline of clinically validated products, and scale its dermatologist-led Centre of Excellence. The company also plans a significant recruitment drive across various functions to bolster its product development and clinical infrastructure, positioning itself for accelerated growth in the competitive beauty and wellness sector.
Innovative Product Portfolio and Market Approach
CHOSEN’s product portfolio encompasses a range of topical formulations and nutraceuticals designed to address key dermatological concerns prevalent among Indian consumers. This includes targeted solutions for pigmentation, skin texture, facial contouring, and hair aging. Notable offerings that have gained traction include the SAFESCREEN NEXGEN sunscreen, formulated for advanced protection, and the CHOSEN Sculpt protocol, a topical contouring system developed with the Indian consumer in mind.
Addressing the Indian Skincare Market with Localized Innovation
Dr. Rajan articulated the company’s mission, stating, “Personal care in India has largely followed global trends that don’t fully reflect local conditions. We are building products grounded in the Indian exposome and genome, with dermatology at the core.” This localized approach resonates with a growing market demand for scientifically validated skincare solutions in India, where dermocosmetics—products bridging the gap between pharmaceuticals and cosmetics—are increasingly gaining consumer acceptance and market share.
Investor Confidence in Clinical Rigor and Market Potential
Investors have shown strong conviction in CHOSEN’s business model, citing its combination of clinical rigor and demonstrated consumer adoption. Fireside Ventures noted that the company’s scientific foundation and repeat consumer engagement were key differentiating factors. Similarly, L’Oréal’s BOLD investment arm emphasized CHOSEN’s embedded dermatologist network and its unwavering commitment to a science-first approach, aligning with the evolving landscape of premium and effective skincare solutions.